ANL (Adlai Nortye) Construction In Progress: $0.00 Mil (As of Dec. 2025)


What is Adlai Nortye Construction In Progress?

Adlai Nortye ANL -1.57% Construction In Progress is $0.00 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye Construction In Progress Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Construction In Progress Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
0.00 0.00 0.00 0.00 0.00

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adlai Nortye Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Adlai Nortye (ANL) has a Construction In Progress of $0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Construction In Progress too high?
Adlai Nortye's current Construction In Progress is $0.00 Mil.
How does Adlai Nortye's Construction In Progress compare to PHAT and AURA?
Adlai Nortye's Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Construction In Progress of $0.00 Mil. The current Construction In Progress is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Construction In Progress is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.